Business context and reporting period
Entity discrepancy: The request names Climb Bio, Inc., but the supplied Form 10-Q is for Eliem Therapeutics, Inc. (Nasdaq: ELYM). This summary covers the filing supplied, not Climb Bio.
The filing reports unaudited results for the quarter and six months ended June 30, 2021. Eliem is a clinical-stage biotechnology company developing treatments for neuronal excitability disorders. It reported no product revenue.
Financial results and liquidity
Amounts below are in millions of dollars except per-share data. The filing reports no debt; margins are not meaningful because the company had no revenue.
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Operating expenses | $8.707 | $1.608 | $15.586 | $3.559 |
| Net loss | $(8.719) | $(1.631) | $(27.320) | $(3.547) |
| Net loss per share attributable to common stockholders | $(3.11) | $(1.12) | $(8.80) | $(2.39) |
| Cash used in operating activities | Not separately provided | Not separately provided | $(15.221) | $(6.093) |
At June 30, 2021, cash was $99.482 million, total assets $107.627 million, and current liabilities $5.713 million. The company had no debt reported. Its accumulated deficit was $55.456 million. Cash increased from $20.487 million at year-end 2020, primarily reflecting $93.939 million of net preferred-stock proceeds during the first half.
After quarter-end, the August 2021 IPO raised estimated net proceeds of $83.1 million. Management estimated cash on hand plus IPO proceeds would fund operations through late 2023, subject to assumptions; the filing also says substantial additional funding will be needed to develop and commercialize its programs.
Material changes versus the prior comparable period
- Second-quarter operating expenses increased to $8.707 million from $1.608 million. R&D expense, including related-party R&D, rose to $5.793 million from $1.360 million, driven by ETX-810 and ETX-155 clinical work and preclinical programs. G&A rose to $2.914 million from $0.248 million, reflecting increased staffing, stock compensation, consulting and legal costs.
- For the first half, operating expenses rose to $15.586 million from $3.559 million. Net loss increased to $27.320 million from $3.547 million; the 2021 amount included an $11.718 million noncash loss from remeasurement of a preferred-stock tranche liability.
- First-half operating cash use increased to $15.221 million from $6.093 million. Financing provided $94.050 million in the first half of 2021, versus none in the comparable 2020 period.
Outlook, commentary, risks and unusual items
- Pipeline outlook: ETX-810 Phase 2a topline results were expected in the first half of 2022. The company expected results from an ETX-155 multiple-ascending-dose extension in Q4 2021, planned a Phase 1b epilepsy trial in the second half of 2021, and planned MDD and perimenopausal-depression Phase 2a trials for the second half of 2021, with first patients expected in early 2022 and topline results in the first half of 2023. These are forward-looking expectations, not reported outcomes.
- Funding and losses: Eliem expected losses and R&D and G&A expenses to increase. It had no approved products or product-sales revenue and stated that future development depends on additional capital, which may not be available on acceptable terms.
- Unusual item: A $11.718 million first-half noncash charge arose from fair-value remeasurement of Series A-1 preferred-stock tranche rights before settlement following ETX-155 Phase 1 milestones. The liability was settled in March 2021 and reclassified to preferred stock.
- Post-period events: The IPO closed August 12, 2021; all outstanding preferred shares converted into 15,345,279 common shares. A 1-for-2 reverse stock split took effect July 29, 2021, and share and per-share figures in the filing reflect the split retroactively.
- Controls and risks: Management said disclosure controls were ineffective at June 30, 2021 because of material weaknesses involving accounting staffing and expertise, formal accounting controls and IT general controls. Remediation was ongoing and the weaknesses had not been remediated. The company also cited clinical-development, third-party manufacturing, financing, intellectual-property and COVID-19 risks. Management said COVID-19 had not materially adversely affected operations or fundraising to date, but future effects remained uncertain.
- Other commitments: Future minimum UK operating-lease payments were approximately $0.7 million as of June 30, 2021. The filing reported no material legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Eliem Therapeutics, Inc., not Climb Bio, Inc.
- Check subsequent filings for actual trial progress and results against the ETX-810 and ETX-155 timelines stated here.
- Review the company’s cash burn and financing needs against the late-2023 runway estimate, which depended on assumptions and included post-quarter IPO proceeds.
- Track remediation and testing of the disclosed material weaknesses in financial reporting controls.
- Reconcile the first-half net loss with the $11.718 million noncash tranche-liability charge and distinguish preferred-stockholder effects from common-stockholder loss per share.